



Ocular Therapeutix™ to Participate at the Cantor Fitzgerald Inaugural Healthcare Conference

June 30, 2015

BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 30, 2015-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Brad Smith, Chief Financial Officer, will present a corporate overview at the Cantor Fitzgerald Inaugural Healthcare Conference on Wednesday, July 8, 2015 at 9:00 a.m. EDT at the Le Parker Meridien Hotel in New York City.

Also at the conference, Scott Corning, Vice President, Sales and Marketing, will participate in a panel discussion entitled, "Emerging Trends in Ophthalmology: Innovative Products, FDA and the Evolving Landscape," at 1:00 p.m. EDT.

A live audio webcast of the corporate presentation can be accessed through the Calendar of Events section of the Company's website at investors.ocutx.com. A replay of the webcast will be available on the Company's website for two weeks following the presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and Phase 2 clinical development for glaucoma, and inflammatory dry eye disease. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20150630005249/en/>

Source: Ocular Therapeutix, Inc.

Investors:

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

bsmith@ocutx.com

or

Burns McClellan on behalf of Ocular Therapeutix

Kimberly Minarovich, 212-213-0006

kminarovich@burnsmc.com

or

Media:

Scott Corning

Vice President of Sales and Marketing

scorning@ocutx.com